manuscript submitted to the *Journal of Clinical Investigation* entitled: "Akt1 promotes physiologic, but antagonizes pathologic, cardiac growth."

• Figures 3A, 3C, and 4A in: Welsh, C.F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M.A., & Assoian, R.K. "Timing of cyclin D1 expression within G1 phase is controlled by Rho." *Nature Cell Biology* 3(11):950–957, 2001.

- Figures 1, 2A, 2B, 3A, 3C, 4A, 4B, 6C, 6D, and 6E in: Roovers, K., & Assoian, R.K. "Effects of rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G(1) phase cyclin-dependent kinases." Mol. Cell Biol. 23(12):4283–4294, 2003. Retracted in Mol. Cell Biol. 26(13):5203, July 2006.
- Figures 1C, 2C, 5B, 5D, 6B and 6D in: Roovers, K., Klein, E.A., Castagnino, P., & Assoian, R.K. "Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression." *Developmental Cell* 5 (2):273–284, 2003. Retracted in *Developmental Cell* 10(5):681, May 2006.

Corrections were recommended by UP for the *Nature Cell Biology* paper.

Dr. Roovers' falsified Western blot data from the publications in *Nature Cell Biology* and from *Developmental Cell* were included in NIH grant applications CA 72639–07 and GM 69064–01.

ORI has implemented the following administrative actions for a period of five (5) years, beginning on June 7, 2007:

(1) Dr. Roovers is debarred from eligibility for any contracting or

subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as "covered transactions" as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and

(2) Dr. Roovers is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

Chris B. Pascal,

Director, Office of Research Integrity.
[FR Doc. E7–13703 Filed 7–13–07; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-07-06BM]

Agency Forms Undergoing Paperwork; Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of

information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–5960 or send an email to: omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974.

Notice of Correction

Title of Project

Randomized Controlled Trial of Routine Screening for Intimate Partner Violence—New—National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention (CDC).

Description of Correction

A 30-day **Federal Register** Notice was published on June 25, 2007 (Vol. 72, No. 121, pp. 34691–34692) describing proposed activities with total estimated annualized burden of 717.7 hours. The annualized total burden hour estimate is correct, however, due to a clerical oversight, the table of Estimated Annualized Burden Hours contained non-annualized figures for the Number of Respondents (i.e., project totals). The corrected table appears below. The total estimated annualized burden hours are 717.7.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Women Seeking Health Care Services	Eligibility Script for Pretest	70 65	1	1/60 15/60
	Follow-up Questionnaire Pretest	59	1	12/60
	Eligibility Script for Main Study	1,533	1	1/60
	Baseline Questionnaire for Main Study	1,227	1	17/60
	Follow-up Questionnaire Main Study	860	1	22/60

Dated: July 9, 2007.

Maryam I. Daneshvar,

Acting Reports Clearance Officer, Centers for Disease Control and Prevention.

[FR Doc. E7–13730 Filed 7–13–07; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243.

Project: National Evaluation of the Protection and Advocacy for Individuals with Mental Illness (PAIMI) Program—NEW

In recognition that systematic evaluation of this and other government programs are part of good management